NeuroSense announces ‘positive’ results from the PARADIGM study

NeuroSense (NRSN) Therapeutics is pleased to announce statistically significant positive results from the 18-month data analysis of the PARADIGM study, evaluating the efficacy of PrimeC in the treatment of Amyotrophic Lateral Sclerosis. These results highlight a significant improvement in ALS Functional Rating Scale-Revised scores and survival rates for patients receiving PrimeC from the start compared to those who started on placebo. The study revealed a significant difference of nearly 8 points in ALSFRS-R between the group treated with PrimeC for 18 months and the group that received placebo for 6 months before transitioning to PrimeC for 12 months. This difference seen between the groups represents a 33% functional improvement, with a highly significant P value of 0.007. In addition, patients on PrimeC for 18 months demonstrated a significantly better survival outcome than those initially on placebo, with a 58% improvement in survival rates. The company anticipates to update on the outcome of the meeting with the FDA in the next several days.